ClinicalTrials.gg
RecruitingNCT07365462Updated Nov 18, 2026

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

A Phase 2 interventional study of NBI-1065890 and Placebo in Tardive Dyskinesia, sponsored by Neurocrine Biosciences. Recruiting at 48 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 18, 2026First sites in 5 new countries30 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Tardive Dyskinesia by Neurocrine Biosciences — 2 open to participants now, 2 under way, none of them phase 3. Tardive Dyskinesia · Neurocrine Biosciences.

Planned enrollment
7th of 12
100 · median 101
Started
2026
the only one that year
Phase 2
5 of 13
1 open now
Registered
13th of 13
by date

Among the 13 studies in Tardive Dyskinesia by Neurocrine Biosciences, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 2, and was the 13th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

2 of the 13 studies in Tardive Dyskinesia by Neurocrine Biosciences are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Tardive Dyskinesia by Neurocrine Biosciences, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.

03

Conditions studied

  • Tardive Dyskinesia

Browse trials for

Keywords

  • Tardive Dyskinesia
  • NBI-1065890
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Medically confirmed diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder (MDD) as defined in the , Fifth Edition (DSM-5) for at least 3 months prior to screening.
  • Medically confirmed diagnosis of neuroleptic-induced TD as defined in the DSM-5 for at least 3 months prior to screening.
  • Moderate or severe TD (AIMS Item 8, severity of abnormal movement overall) as assessed by a blinded, external AIMS video reviewer using a video recording of the participant's AIMS assessment administered at the clinical site by a blinded, certified site AIMS rater. The AIMS dyskinesia total score (sum of Items 1 to 7) must be ≥6 as assessed by the blinded, external AIMS video reviewer.

Key Exclusion Criteria:

  • Comorbid parkinsonism (drug-induced or otherwise) or more than a minimal level of extrapyramidal signs/symptoms, as documented by a score on the Modified Simpson-Angus Scale (mSAS) (excluding Items 8 and 10) >6 at screening or Day -1 (baseline) or a score >3 in any one item (excluding Items 8 and 10).
  • Barnes Akathisia Rating Scale (BARS) global clinical assessment score ≥2 at screening or Day -1.
  • Brief Psychiatric Rating Scale (BPRS) total score ≥50 at screening or Day -1.
  • Hospitalized for schizophrenia, schizoaffective disorder, bipolar disorder, or MDD within 6 months of screening.
  • Participant has an unstable medical condition or unstable chronic disease.
  • Any known history of neuroleptic malignant syndrome (NMS).

Note: Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    NBI-1065890

    Participants will receive NBI-1065890.

    Drug: NBI-1065890

  • Placebo comparator
    Placebo

    Participants will receive placebo matching NBI-1065890.

    Drug: Placebo

Interventions

  • DrugNBI-1065890

    Oral administration

  • DrugPlacebo

    Oral administration

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 8 Based on the Blinded Central AIMS Video Raters' Assessment

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Percentage of Participants Who Are a Clinical Global Impression - Improvement (CGI-I) Responder 1 at Week 8

    Time frame: Week 8

07

Study locations

48 of 48 sites recruiting
  • Neurocrine Clinical Site
    Bryant, Arkansas 72022, United States
    Recruiting
  • Neurocrine Clinical Site
    Chino, California 91710, United States
    Recruiting
  • Neurocrine Clinical Site
    Fountain Valley, California 92708, United States
    Recruiting
  • Neurocrine Clinical Site
    Huntington Beach, California 92648, United States
    Recruiting
  • Neurocrine Clinical Site
    Long Beach, California 90807, United States
    Recruiting
  • Neurocrine Clinical Site
    San Diego, California 92123, United States
    Recruiting
  • Neurocrine Clinical Site
    Temecula, California 92591, United States
    Recruiting
  • Neurocrine Clinical Site
    Torrance, California 90501, United States
    Recruiting
  • Neurocrine Clinical Site
    Boca Raton, Florida 33486, United States
    Recruiting
  • Neurocrine Clinical Site
    Bonita Springs, Florida 34134, United States
    Recruiting
  • Neurocrine Clinical Site
    Hialeah, Florida 33012, United States
    Recruiting
  • Neurocrine Clinical Site
    Hialeah, Florida 33013, United States
    Recruiting
  • Neurocrine Clinical Site
    Miami, Florida 33176, United States
    Recruiting
  • Neurocrine Clinical Site
    Orange City, Florida 32763, United States
    Recruiting
  • Neurocrine Clinical Site
    Port Charlotte, Florida 33980, United States
    Recruiting
  • Neurocrine Clinical Site
    Tampa, Florida 33629, United States
    Recruiting
  • Neurocrine Clinical Site
    Atlanta, Georgia 30328, United States
    Recruiting
  • Neurocrine Clinical Site
    Marietta, Georgia 30060, United States
    Recruiting
  • Neurocrine Clinical Site
    Naperville, Illinois 60563, United States
    Recruiting
  • Neurocrine Clinical Site
    Ann Arbor, Michigan 48105, United States
    Recruiting
  • Neurocrine Clinical Site
    Bloomfield Hills, Michigan 48302, United States
    Recruiting
  • Neurocrine Clinical Site
    Saint Charles, Missouri 63304, United States
    Recruiting
  • Neurocrine Clinical Site
    Lincoln, Nebraska 68526, United States
    Recruiting
  • Neurocrine Clinical Site
    Commack, New York 11725, United States
    Recruiting
  • Neurocrine Clinical Site
    Charlotte, North Carolina 28211, United States
    Recruiting
  • Neurocrine Clinical Site
    Beachwood, Ohio 44122, United States
    Recruiting
  • Neurocrine Clinical Site
    Fairlawn, Ohio 44333, United States
    Recruiting
  • Neurocrine Clinical Site
    Austin, Texas 78754, United States
    Recruiting
  • Neurocrine Clinical Site
    Fort Worth, Texas 76104, United States
    Recruiting
  • Neurocrine Clinical Site
    Houston, Texas 77030, United States
    Recruiting
  • Neurocrine Clinical Site
    Stafford, Texas 77477, United States
    Recruiting
  • Neurocrine Clinical Site
    Cherven Bryag, 5980, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Kardzhali, 6600, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Novi Iskar, 1282, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Plovdiv, 4000, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Plovdiv, 4004, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Sofia, 1164, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Sofia, 1618, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Varna, 9020, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Veliko Tarnovo, 5000, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Kladno, 272 01, Czechia
    Recruiting
  • Neurocrine Clinical Site
    Pilsen, 301 00, Czechia
    Recruiting
  • Neurocrine Clinical Site
    San Juan, 00926, Puerto Rico
    Recruiting
  • Neurocrine Clinical Site
    Brasov, 500299, Romania
    Recruiting
  • Neurocrine Clinical Site
    Galati, 800183, Romania
    Recruiting
  • Neurocrine Clinical Site
    Bojnice, 972 01, Slovakia
    Recruiting
  • Neurocrine Clinical Site
    Dubnica nad Váhom, 01841, Slovakia
    Recruiting
  • Neurocrine Clinical Site
    Košice, 040 01, Slovakia
    Recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 26, 2026
StartActual
Feb 6, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Mar 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
30 sites added — first sites in Bulgaria, Puerto Rico, Czechia, Romania and Slovakia
Show 30 added (13 United States, 9 Bulgaria, 3 Slovakia, 2 Czechia, 2 Romania, 1 Puerto Rico)
  • Neurocrine Clinical Site · San Diego, United States
  • Neurocrine Clinical Site · Hialeah, United States
  • Neurocrine Clinical Site · Port Charlotte, United States
  • Neurocrine Clinical Site · Atlanta, United States
  • Neurocrine Clinical Site · Naperville, United States
  • Neurocrine Clinical Site · Ann Arbor, United States
  • Neurocrine Clinical Site · Bloomfield Hills, United States
  • Neurocrine Clinical Site · Saint Charles, United States
  • Neurocrine Clinical Site · Commack, United States
  • Neurocrine Clinical Site · Fairlawn, United States
  • Neurocrine Clinical Site · Austin, United States
  • Neurocrine Clinical Site · Stafford, United States
  • Neurocrine Clinical Site · Cherven Bryag, Bulgaria
  • Neurocrine Clinical Site · Plovdiv, Bulgaria
  • Neurocrine Clinical Site · Sofia, Bulgaria
  • Neurocrine Clinical Site · Varna, Bulgaria
  • Neurocrine Clinical Site · San Juan, Puerto Rico
  • Neurocrine Clinical Site · Charlotte, United States
  • Neurocrine Clinical Site · Kardzhali, Bulgaria
  • Neurocrine Clinical Site · Novi Iskar, Bulgaria
  • Neurocrine Clinical Site · Plovdiv, Bulgaria
  • Neurocrine Clinical Site · Sofia, Bulgaria
  • Neurocrine Clinical Site · Veliko Tarnovo, Bulgaria
  • Neurocrine Clinical Site · Kladno, Czechia
  • Neurocrine Clinical Site · Pilsen, Czechia
  • Neurocrine Clinical Site · Brasov, Romania
  • Neurocrine Clinical Site · Galati, Romania
  • Neurocrine Clinical Site · Bojnice, Slovakia
  • Neurocrine Clinical Site · Dubnica nad Váhom, Slovakia
  • Neurocrine Clinical Site · Košice, Slovakia
across 2 updates, Nov 12, 2026 – Nov 18, 2026
Show all 2 updates
  1. Nov 18, 2026
    13 sites added — first sites in Czechia, Romania and Slovakia
    Show 13 added (5 Bulgaria, 3 Slovakia, 2 Czechia, 2 Romania, 1 United States)
    • Neurocrine Clinical Site · Charlotte, United States
    • Neurocrine Clinical Site · Kardzhali, Bulgaria
    • Neurocrine Clinical Site · Novi Iskar, Bulgaria
    • Neurocrine Clinical Site · Plovdiv, Bulgaria
    • Neurocrine Clinical Site · Sofia, Bulgaria
    • Neurocrine Clinical Site · Veliko Tarnovo, Bulgaria
    • Neurocrine Clinical Site · Kladno, Czechia
    • Neurocrine Clinical Site · Pilsen, Czechia
    • Neurocrine Clinical Site · Brasov, Romania
    • Neurocrine Clinical Site · Galati, Romania
    • Neurocrine Clinical Site · Bojnice, Slovakia
    • Neurocrine Clinical Site · Dubnica nad Váhom, Slovakia
    • Neurocrine Clinical Site · Košice, Slovakia
  2. Nov 12, 2026
    17 sites added — first sites in Bulgaria and Puerto Rico
    Show 17 added (12 United States, 4 Bulgaria, 1 Puerto Rico)
    • Neurocrine Clinical Site · San Diego, United States
    • Neurocrine Clinical Site · Hialeah, United States
    • Neurocrine Clinical Site · Port Charlotte, United States
    • Neurocrine Clinical Site · Atlanta, United States
    • Neurocrine Clinical Site · Naperville, United States
    • Neurocrine Clinical Site · Ann Arbor, United States
    • Neurocrine Clinical Site · Bloomfield Hills, United States
    • Neurocrine Clinical Site · Saint Charles, United States
    • Neurocrine Clinical Site · Commack, United States
    • Neurocrine Clinical Site · Fairlawn, United States
    • Neurocrine Clinical Site · Austin, United States
    • Neurocrine Clinical Site · Stafford, United States
    • Neurocrine Clinical Site · Cherven Bryag, Bulgaria
    • Neurocrine Clinical Site · Plovdiv, Bulgaria
    • Neurocrine Clinical Site · Sofia, Bulgaria
    • Neurocrine Clinical Site · Varna, Bulgaria
    • Neurocrine Clinical Site · San Juan, Puerto Rico
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07365462
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
Feb 6, 2026
Primary completion
Feb 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Neurocrine Medical Information Call Center
Contact
medinfo@neurocrine.com
1-877-641-3461
Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion